Filtered By:
Source: World Pharma News
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Hundreds of thousands of strokes may be preventable each year
Many patients with an irregular heartbeat, known as atrial fibrillation, are not receiving recommended blood thinning medication they need to prevent strokes, according to a study published today in the Journal of the American College of Cardiology. People who have atrial fibrillation are at a very high risk for stroke. However, if they take blood thinners known as oral anticoagulants (OACs), it can reduce their risk by two-thirds.
Source: World Pharma News - May 15, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Neurological diseases cost the US nearly $800 billion per year
A new paper published in the Annals of Neurology reports the most common neurological diseases pose a serious annual financial burden for the nation. The report notes that the current estimated annual cost to American society of just nine of the most common neurological diseases is staggering, totaling $789 billion in 2014 dollars. These conditions include Alzheimer's disease and other dementias, low back pain, stroke, traumatic brain injury, migraine, epilepsy, multiple sclerosis, spinal cord injury, and Parkinson's disease.
Source: World Pharma News - March 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto ®) shows overwhelming efficacy and meets primary endpoint early
Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint ahead of time.
Source: World Pharma News - February 14, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Amgen announces Repatha ® (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
Amgen (NASDAQ:AMGN) has announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
Source: World Pharma News - February 3, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
The European Stroke Organisation and Boehringer Ingelheim launch the "Angels Initiative"
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. It is also a great challenge for the medical personnel treating the patient, trying to save their patients' life and independence.
Source: World Pharma News - July 21, 2016 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
'Mediterranean' diet linked to lower risk of heart attacks & strokes in heart patients
A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease, according to a study of over 15,000 people in 39 countries around the world. The research also showed that eating greater amounts of healthy food was more important for these people than avoiding unhealthy foods, such as refined grains, sweets, desserts, sugared drinks and deep-fried food - a "Western" diet.
Source: World Pharma News - April 27, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Immune cells help the brain to self-heal after a stroke
After a stroke, there is inflammation in the damaged part of the brain. Until now, the inflammation has been seen as a negative consequence that needs to be abolished as soon as possible. But, as it turns out, there are also some positive sides to the inflammation, and it can actually help the brain to self-repair.
Source: World Pharma News - April 15, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke
AstraZeneca today announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA).
Source: World Pharma News - March 23, 2016 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Diabetes drug may prevent recurring strokes
Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.
Source: World Pharma News - February 18, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
